DAILYPEPTIDE GUIDE
Unstandardized combination

Wolverine

BPC-157 + TB-500

Uncertain or Concerning

Video guide

Video guides are coming soon.

Identity

Commercial or common name

Wolverine. This name is not standardized.

Variants

Reported formulation variants

  • Alternate ratios and product-specific formulations
Combination evidence

What the combination shows

No adequate human combination evidence was identified in the static MVP review. Component-level findings do not transfer to the combination.

Regulatory

Status

Unapproved / RUO. No approval is implied by use of a commercial or community name.

Human research

Combination trial status

No validated human combination trial identified

Quality

Stability and compatibility

Compatibility, sterility and stability are not established across marketed variants

Claims

Common marketing claims

  • Tissue repair
  • Faster recovery
Evidence-based conclusion

Bottom line

This named stack should be evaluated as an unstandardized combination. It does not inherit the evidence score of its strongest component.

Individual component evidence

Experimental / RUOVerification pending

BPC-157

Body protection compound 157

A research peptide often marketed for gut, tendon and injury recovery.

Tier 3Unapproved / RUO
Experimental / RUOVerification pending

TB-500

Thymosin beta-4 fragment

A commercial research label associated with thymosin beta-4-related products.

Tier 3Unapproved / RUO